What is HC Wainwright’s Estimate for AKRO Q1 Earnings?

Akero Therapeutics, Inc. (NASDAQ:AKRO) – HC Wainwright issued their Q1 2026 earnings per share estimates for Akero Therapeutics in a report issued on Thursday, September 4th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of ($0.96) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $72.00 price target on the stock. The consensus estimate for Akero Therapeutics’ current full-year earnings is ($3.99) per share. HC Wainwright also issued estimates for Akero Therapeutics’ Q2 2026 earnings at ($0.99) EPS, Q3 2026 earnings at ($1.02) EPS and Q4 2026 earnings at ($1.04) EPS.

A number of other analysts also recently commented on the company. Cowen started coverage on Akero Therapeutics in a research report on Monday, August 4th. They set a “buy” rating on the stock. TD Cowen started coverage on Akero Therapeutics in a research report on Monday, August 4th. They set a “buy” rating and a $76.00 target price on the stock. Wall Street Zen upgraded Akero Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Bank of America boosted their target price on Akero Therapeutics from $63.00 to $64.00 and gave the stock a “buy” rating in a research report on Tuesday, May 27th. Finally, Citigroup reduced their price objective on Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Akero Therapeutics currently has an average rating of “Buy” and a consensus target price of $81.14.

Akero Therapeutics Stock Performance

Shares of AKRO opened at $44.72 on Friday. The company has a 50-day simple moving average of $49.62 and a 200-day simple moving average of $46.73. The company has a quick ratio of 12.66, a current ratio of 12.66 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $3.58 billion, a PE ratio of -22.36 and a beta of -0.24. Akero Therapeutics has a 52-week low of $21.34 and a 52-week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Friday, August 8th. The company reported ($0.86) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.11. During the same period in the previous year, the company earned ($0.81) earnings per share.

Institutional Investors Weigh In On Akero Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC acquired a new position in Akero Therapeutics during the second quarter valued at approximately $28,000. Northwest & Ethical Investments L.P. acquired a new position in Akero Therapeutics during the first quarter valued at approximately $32,000. GF Fund Management CO. LTD. acquired a new position in Akero Therapeutics during the fourth quarter valued at approximately $41,000. PNC Financial Services Group Inc. lifted its position in Akero Therapeutics by 30.8% during the first quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company’s stock valued at $67,000 after buying an additional 390 shares in the last quarter. Finally, TD Waterhouse Canada Inc. acquired a new stake in shares of Akero Therapeutics in the second quarter valued at about $71,000.

Insider Activity at Akero Therapeutics

In other Akero Therapeutics news, COO Jonathan Young sold 12,500 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $46.08, for a total transaction of $576,000.00. Following the sale, the chief operating officer directly owned 197,484 shares of the company’s stock, valued at $9,100,062.72. This trade represents a 5.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Patrick Lamy sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $52.88, for a total transaction of $105,760.00. Following the sale, the vice president directly owned 29,891 shares in the company, valued at $1,580,636.08. This represents a 6.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 197,406 shares of company stock worth $10,144,055 over the last three months. Company insiders own 7.07% of the company’s stock.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.